New study tests bone tumor drug in chinese patients
NCT ID NCT04586660
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 4 study tests the drug XGEVA (denosumab) in 36 Chinese adults and teens with giant cell tumor of bone, a rare but aggressive bone tumor. Participants receive injections every 4 weeks. The goal is to see if the drug shrinks tumors or helps make surgery easier. The study is active but no longer recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Denosumab (XGEVA)
What this could lead to
If successful, this could confirm that denosumab helps shrink or control giant cell tumors of the bone in Chinese patients, offering a non-surgical option.
What could go wrong
This is a small, single-country study (36 participants) with no placebo group. Results may not apply to other populations, and long-term risks like jaw problems or low calcium levels are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GIANT CELL TUMOR OF BONE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Jishuitan Hospital
Beijing, Beijing Municipality, 100035, China
-
Harbin Meidical University Cancer Hospital
Harbin, Heilongjiang, 150000, China
-
National Taiwan University Hospital
Taipei, 10002, Taiwan
-
Peking University Peoples Hospital
Beijing, Beijing Municipality, 100044, China
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510663, China
-
Taipei Veterans General Hospital
Taipei, 11217, Taiwan
-
Tangdu Hospital of Air Force Medical University
Xi'an, Shaanxi, 710032, China
-
The First Affiliated Hospital of Fujian Medical University
Fuzhou, Fujian, 350005, China
-
The Second Affiliated hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310052, China
-
The Third Affiliated Hospital Of Southern Medical University
Guangzhou, Guangdong, 510630, China